Navigation Links
Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies

A recent research has found that the cox-2 inhibitor celecoxib, a common pain reliever used to treat arthritis, may reduce the risk of the most common cause of brain damage in premature babies.

The work involves shoring up blood vessels in a part of the brain that in premature infants is very delicate and susceptible to dangerous bleeding, which has an effect on an approximate 12,000 children a year, leaving many everlastingly affected by cerebral palsy, mental retardation, and seizures.

"Stabilizing the blood vessels right before the baby is born is a tremendous opportunity to save the baby from potentially lifelong complications," said Maiken Nedergaard, M.D., Ph.D., a neuroscientist at the University of Rochester Medical Center who is presenting the results at a neuroscience meeting, Brain '07, in Osaka, Japan May 20-23.

The laboratory research was done principally in a laboratory at New York Medical College led by neonatologist Praveen Ballabh, M.D.

The research is based on extensive brain studies of infants who died prematurely as well as on findings with newborn rabbits, whose brains bear a resemblance to those of premature babies in some very significant ways. The medication would need to be tested thoroughly in pregnant women before being considered as a treatment for their babies. But the investigators indicate that celecoxib is already used widely in people, including pregnant women, making a clinical trial in people possible.

The researchers focused on a part of the brain known in budding infants as the germinal matrix, a temporary formation that is the origin of all brain cells in a baby. The structure runs like an uneven coastline just below spaces in the brain called ventricles, and in premature infants it's enormously active, manufacturing new brain cells that wander and settle into other parts of the brain.

"This is a very, very important part of the brain, from wh
'"/>




Page: 1 2 3

Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
(Date:10/13/2008)... come with other NSAID pain relievers, experts say...- When the pain killer Vioxx was pulled from the m...he risk of heart attack, stroke and death -- many ... , But a new study finds that "the risk was in...or approximately a year," said co-author Dr. Rober...
(Date:10/13/2008)...sored stop-smoking programs for inpatients that in...th significantly improve patients, ability to stay...ograms offered at hospitals around the world finds...ease participant,s chances of success by 65 percen...the Tobacco Research and Treatment Center at Massa...
(Date:10/13/2008)...udy suggests that the combination of low plasma le...the sun is associated with certain forms of the ey...according to a report in the October issue of Arc... journals. , "The retina is vulnerable to the d...ckground information in the article. "While wavele...
(Date:10/13/2008)...d smoking cessation programs, along with referrals...d with increased rates of quitting smoking followi... 13, 2008, issue of Archives of Internal Medicine...iversity researchers studied 639 patients who smok...attack. Six months later, 297 of the patients app...
Breaking Medicine News(10 mins):Health News:Vioxx's Heart Risk Lingered Long After Use Ended 2Health News:Vioxx's Heart Risk Lingered Long After Use Ended 3Health News:Intensive support programs can help hospitalized smokers stay smoke-free 2Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2
...g technique for prostate cancers has been found ou...e traditional examination. In the traditional exam...samples from the prostate gland. At Ohio State U...at it is better to take more samples. Dr.Robert Ba...
...in helping people deal with stress. There has been... helps people improve both their physical and ment...versity in the US have been looking at how a medit...aining' can help people who describe themselves as...
...lly indicated by itchy flaky scalp to give it a m...u can treat dandruff by using a medicated shampoo,... from time to time, as individual products may los...th the shampoo every day or so, and make sure it a...
...rket with an advertising blitz--but no proof it wo...seasonal allergies, one tiny blue pill," proclaim ...ring-Plough makes Claritin, the nation's best-sell...mber, the Food and Drug Administration is expected...
Other Medicine News:
(Date:10/13/2008)...e Higher Sensitivity and Specificity, than Other ... preferred test in all phases of t...Newswire/ -- AT First Diagnostic LLC an,emerging w... kits, today,announced that a recent evaluation co...rch of the FirstVue(TM) HBSAG Test, was released a...
(Date:10/12/2008)... Combination with Chemotherapy, FREMONT, Calif. O..., a,development-stage pharmaceutical company disco...)-based therapeutics, today announced that the,jou... of siRNA targeting,its proprietary target gene ag...ition dated October 1, 2008. The paper, entitled "...
(Date:10/10/2008)...wswire/ -- Diplomat Specialty,Pharmacy announced t...Specialty Pharmacy to be one of only three sites t...ptimization Study for Multiple Sclerosis (TOP MS)....xamine the benefits of a,specialty pharmacy therap...patient outcomes. Targeted patient outcomes will i...
(Date:10/10/2008)...swire/ -- TriReme Medical Inc. (TMI),announced tod...nformite,Europeenne) marking and commercialize in ...ique main vessel stent system specially designed f...nting the next generation in bifurcation stenting,...rter of the 2.2 million,angioplasty procedures per...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Spectros Corporation Reports 2007 Year Over Year Sales Rise 36 25 4279 1Spectros Corporation Reports 2007 Year Over Year Sales Rise 36 25 4279 2China Kangtai Cactus Biotech Inc Obtains 24500 000 Equity Financing 4276 1China Kangtai Cactus Biotech Inc Obtains 24500 000 Equity Financing 4276 2Abbotts XIENCE 28TM 29 V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years 1639 1Abbotts XIENCE 28TM 29 V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years 1639 2Abbotts XIENCE 28TM 29 V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years 1639 3Spirit II Results Support Strength of Boston Scientifics Two Drug Eluting Stent Platforms 1636 1Spirit II Results Support Strength of Boston Scientifics Two Drug Eluting Stent Platforms 1636 2Spirit II Results Support Strength of Boston Scientifics Two Drug Eluting Stent Platforms 1636 3Spirit II Results Support Strength of Boston Scientifics Two Drug Eluting Stent Platforms 1636 4
... 7, 2007 - ApoCell, Inc. presented the,results of ... of,Chicago and ApoCell at the 2007 annual meeting...O) held in Chicago in early June.,The study showed...,assay technology provides reliable predictive dat...fit of treating aggressive head,and neck cancer pa...
...WIRE)--Jun 8, 2007 - NuPathe Inc., a,privately hel...d,positive results from an initial Phase I study o...igraine being developed,by NuPathe., NP101 combine...tic transdermal technology with sumatriptan, the m... in the United,States. Sumatriptan is also the act...
Other Medicine Technology:ApoCell's Cancer Predictive Index Helps Oncologists Select the Most,Effective Targeted Drug Therapy 2NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 2NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 3
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: